Wednesday, April 1, 2020

Novartis scraps sale of assets to Aurobindo Pharma after failing to get FTC nod

Novartis scraps sale of assets to Aurobindo Pharma after failing to get FTC nod Novartis said the decision to terminate the sale of Sandoz US#39;s generic oral solids and dermatology businesses was taken after the companies did not get approval from the U.S. Federal Trade Commission within anticipated timelines.

from Moneycontrol Business News https://ift.tt/2X3yjLJ
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

FII exodus deepens in 2026 at Rs 1.75 lakh crore as April outflows swell to Rs 43,967 crore; FOMC next trigger

Foreign institutional investors offloaded Indian equities worth Rs 17,140 crore last week, extending April's outflows to Rs 43,967 crore...